ARWR – Arrowhead Pharmaceuticals, Inc.
Float Short %
9.92
Margin Of Safety %
Put/Call OI Ratio
0.37
EPS Next Q Diff
1.1
EPS Last/This Y
4.82
EPS This/Next Y
-2.98
Price
29.71
Target Price
44.08
Analyst Recom
1.57
Performance Q
83.23
Relative Volume
1.34
Beta
1.06
Ticker: ARWR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | ARWR | 20.51 | 0.44 | 0.06 | 32242 |
| 2025-08-18 | ARWR | 19.9 | 0.40 | 0.20 | 26808 |
| 2025-08-19 | ARWR | 19.85 | 0.40 | 1.46 | 28010 |
| 2025-08-20 | ARWR | 20.21 | 0.40 | 0.43 | 28298 |
| 2025-08-21 | ARWR | 20.75 | 0.41 | 0.25 | 28722 |
| 2025-08-22 | ARWR | 21.31 | 0.41 | 0.74 | 29249 |
| 2025-08-25 | ARWR | 20.74 | 0.40 | 0.00 | 29262 |
| 2025-08-26 | ARWR | 21.19 | 0.38 | 0.06 | 30823 |
| 2025-08-27 | ARWR | 21.8 | 0.38 | 0.27 | 30851 |
| 2025-08-28 | ARWR | 22.34 | 0.38 | 0.02 | 30972 |
| 2025-08-29 | ARWR | 22.04 | 0.37 | 0.65 | 32136 |
| 2025-09-02 | ARWR | 25.69 | 0.37 | 0.27 | 32497 |
| 2025-09-03 | ARWR | 27.78 | 0.39 | 0.21 | 33995 |
| 2025-09-04 | ARWR | 28 | 0.40 | 0.11 | 35696 |
| 2025-09-05 | ARWR | 29.08 | 0.39 | 0.09 | 37114 |
| 2025-09-08 | ARWR | 27.18 | 0.38 | 0.56 | 37881 |
| 2025-09-09 | ARWR | 27.74 | 0.38 | 0.45 | 37441 |
| 2025-09-10 | ARWR | 28.94 | 0.38 | 0.25 | 37325 |
| 2025-09-11 | ARWR | 29.71 | 0.38 | 1.59 | 37343 |
| 2025-09-12 | ARWR | 29.72 | 0.37 | 0.24 | 38505 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | ARWR | 20.50 | 83.7 | -113.4 | -0.15 |
| 2025-08-18 | ARWR | 19.90 | 83.7 | -87.5 | -0.15 |
| 2025-08-19 | ARWR | 19.86 | 84.5 | -93.2 | -0.13 |
| 2025-08-20 | ARWR | 20.22 | 84.5 | -97.5 | -0.13 |
| 2025-08-21 | ARWR | 20.75 | 84.5 | -99.5 | -0.13 |
| 2025-08-22 | ARWR | 21.32 | 84.5 | -99.5 | -0.13 |
| 2025-08-25 | ARWR | 20.70 | 84.5 | -87.7 | -0.13 |
| 2025-08-26 | ARWR | 21.18 | 84.5 | -98.5 | -0.13 |
| 2025-08-27 | ARWR | 21.79 | 84.5 | -99.8 | -0.13 |
| 2025-08-28 | ARWR | 22.34 | 84.5 | -99.0 | -0.13 |
| 2025-08-29 | ARWR | 22.02 | 84.5 | -90.8 | -0.13 |
| 2025-09-02 | ARWR | 25.70 | 84.5 | -128.0 | -0.13 |
| 2025-09-03 | ARWR | 27.81 | 84.5 | -110.3 | -0.13 |
| 2025-09-04 | ARWR | 27.99 | 84.5 | -95.1 | -0.13 |
| 2025-09-05 | ARWR | 29.08 | 84.5 | -101.3 | -0.13 |
| 2025-09-08 | ARWR | 27.17 | 84.5 | -81.0 | -0.13 |
| 2025-09-09 | ARWR | 27.74 | 81.1 | -97.9 | -0.18 |
| 2025-09-10 | ARWR | 28.90 | 81.1 | -102.1 | -0.18 |
| 2025-09-11 | ARWR | 29.72 | 81.1 | -99.4 | -0.18 |
| 2025-09-12 | ARWR | 29.71 | 81.1 | -93.7 | -0.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | ARWR | -2.10 | 4.67 | 11.22 |
| 2025-08-18 | ARWR | -2.15 | 3.96 | 11.23 |
| 2025-08-19 | ARWR | -2.14 | 3.96 | 11.23 |
| 2025-08-20 | ARWR | -2.14 | 3.96 | 11.23 |
| 2025-08-21 | ARWR | -2.14 | 3.96 | 10.08 |
| 2025-08-22 | ARWR | -4.81 | 3.96 | 10.08 |
| 2025-08-25 | ARWR | -4.81 | 0.46 | 10.08 |
| 2025-08-26 | ARWR | -4.81 | 0.46 | 10.08 |
| 2025-08-27 | ARWR | -4.81 | 0.46 | 10.12 |
| 2025-08-28 | ARWR | -4.81 | 0.46 | 10.12 |
| 2025-08-29 | ARWR | -4.81 | 0.46 | 10.12 |
| 2025-09-02 | ARWR | -4.81 | 0.57 | 10.12 |
| 2025-09-03 | ARWR | -4.81 | 0.57 | 10.12 |
| 2025-09-04 | ARWR | -4.81 | 0.57 | 10.12 |
| 2025-09-05 | ARWR | -4.94 | 0.57 | 10.12 |
| 2025-09-08 | ARWR | -2.14 | 0.58 | 10.12 |
| 2025-09-09 | ARWR | -2.14 | 0.58 | 10.12 |
| 2025-09-10 | ARWR | -2.14 | 0.58 | 10.12 |
| 2025-09-11 | ARWR | -2.14 | 0.58 | 9.92 |
| 2025-09-12 | ARWR | -2.14 | 0.58 | 9.92 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.26
Avg. EPS Est. Current Quarter
-0.26
Avg. EPS Est. Next Quarter
-0.16
Insider Transactions
-2.14
Institutional Transactions
0.58
Beta
1.06
Average Sales Estimate Current Quarter
157
Average Sales Estimate Next Quarter
173
Fair Value
Quality Score
31
Growth Score
36
Sentiment Score
85
Actual DrawDown %
68.3
Max Drawdown 5-Year %
-89
Target Price
44.08
P/E
Forward P/E
PEG
P/S
7.17
P/B
7.86
P/Free Cash Flow
EPS
-1.26
Average EPS Est. Cur. Y
-0.18
EPS Next Y. (Est.)
-3.16
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-25.9
Relative Volume
1.34
Return on Equity vs Sector %
-53.3
Return on Equity vs Industry %
-40.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
-93.7
Arrowhead Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 609
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
stock quote shares ARWR – Arrowhead Pharmaceuticals, Inc. Stock Price stock today
news today ARWR – Arrowhead Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ARWR – Arrowhead Pharmaceuticals, Inc. yahoo finance google finance
stock history ARWR – Arrowhead Pharmaceuticals, Inc. invest stock market
stock prices ARWR premarket after hours
ticker ARWR fair value insiders trading